Novel Immunotherapies for B-Cell Lymphomas and Leukemias

被引：1

作者：

Tees, Michael T. ^{[1
]}

Sokol, Lubomir ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol, 12902 Magnolia Dr, Tampa, FL 33612 USA

来源：

AMERICAN JOURNAL OF THERAPEUTICS | 2016年 / 23卷 / 05期

关键词：

non-Hodgkin lymphoma; Hodgkin lymphoma; B-cell neoplasms; immunotherapy; radioimmunotherapy; monoclonal antibody; antibody-drug conjugate; NON-HODGKIN-LYMPHOMA; PHASE-I TRIAL; IMMUNOCONJUGATE INOTUZUMAB OZOGAMICIN; MONOCLONAL-ANTIBODY LUCATUMUMAB; INNATE IMMUNE-RESPONSES; OPEN-LABEL; BRENTUXIMAB VEDOTIN; FOLLICULAR LYMPHOMA; CLINICAL ACTIVITY; PLUS RITUXIMAB;

D O I：

10.1097/MJT.0000000000000145

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Current immunotherapeutic agents under investigation have the potential to significantly expand our ability to effectively treat B-cell malignancies. New disease targets, novel strategies to deliver therapy, and advanced agents that work to manipulate the immune system are a few of the ways immunotherapy has quickly evolved. Novel targeted and immune-modifying therapies may demonstrate early potential but unique toxicities and other limitations, such as difficulties in administration, must also be acknowledged. This review provides a comprehensive assessment of the current immunotherapies under investigation against B-cell malignancies.

引用

页码：E1157 / E1181

页数：25

共 50 条

[21] Application of flow cytometry immunophenotypic analysis for the diagnosis of mature B-cell lymphomas/leukemias
Fang, Hong
Wang, Sa A.
Medeiros, L. Jeffrey
Wang, Wei
HUMAN PATHOLOGY, 2025, 156
[22] Role of MicroRNAs in B Cell Leukemias and Lymphomas
Schmidt, A.
Kueppers, R.
CURRENT MOLECULAR MEDICINE, 2014, 14 (05) : 580 - 597
[23] Genetic background and evolution of relapses in aggressive B-cell lymphomas
Juskevicius, Darius
Dirnhofer, Stephan
Tzankov, Alexandar
HAEMATOLOGICA, 2017, 102 (07) : 1139 - 1149
[24] Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas
Yi, Jun Ho
BLOOD RESEARCH, 2021, 56 : 1 - 4
[25] CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
Chavez, Julio C.
Bachmeier, Christina
Kharfan-Dabaja, Mohamed A.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10 : 1 - 20
[26] Novel treatments in B cell non-Hodgkin's lymphomas
Sawalha, Yazeed
Maddocks, Kami
BMJ-BRITISH MEDICAL JOURNAL, 2022, 377
[27] Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development
Kubuschok, Boris
Trepel, Martin
EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (07) : 733 - 745
[28] Targeted immunotherapies to consider for B Cell non-hodgkin lymphoma
Namoglu, Esin C.
Hughes, Mitchell E.
Nasta, Sunita D.
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (05): : 317 - 332
[29] Treatment of diffuse large B-cell lymphomas
C. Zwick
N. Murawski
Michael Pfreundschuh
memo - Magazine of European Medical Oncology, 2009, 2 (3) : 150 - 153
[30] Ibrutinib in B-cell Lymphomas
Maddocks, Kami
Blum, Kristie A.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (02) : 226 - 237

← 1 2 3 4 5 →